Boundless Bio, Inc.: Business Overview, Financials & Competitive Analysis
Boundless Bio, Inc. scores 3/10 on the AskCyborg Cyborg Score (Challenged). Early-stage oncology biotech with novel ecDNA-targeting approach requires successful clinical trial readouts and significant capital to reach commercialization. The company has a market cap of $24.4M with EPS (TTM) of -2.66. It is currently unprofitable and not forecast to become profitable over the next 3 years. As a pre-revenue.
What is Boundless Bio, Inc.'s industry? Boundless Bio, Inc. (boundlessbio.com) operates in Pharmaceutical/Biotechnology - Clinical-Stage Oncology. AskCyborg classifies Boundless Bio, Inc. under Pharmaceutical/Biotechnology - Clinical-Stage Oncology in its company registry.
Boundless Bio is a clinical-stage oncology company developing cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by interrogating extrachromosomal DNA (ecDNA). The company targets...
Cyborg Score thesis
Early-stage oncology biotech with novel ecDNA-targeting approach requires successful clinical trial readouts and significant...
Read the full analyst-debate transcript →Get the Latest Boundless Bio, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeBoundless Bio, Inc. Overview
Pro stress-test →Boundless Bio is a clinical-stage oncology company developing cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by interrogating extrachromosomal DNA (ecDNA). The company targets ecDNA, a root cause of oncogene amplification observed in more than 17% of cancer patients.
Strategic Profile
Pro stress-test →The company uses its proprietary Spyglass platform to identify targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. Its lead product candidate is BBI-355, an ecDNA-directed therapeutic candidate and oral inhibitor of checkpoint kinase 1 in Phase 1/2 clinical trial in patients with oncogene amplified cancers.
Competitive Landscape
Pro stress-test →Boundless Bio competes in the clinical-stage oncology space against other cancer therapeutics developers. The company's unique focus on ecDNA-targeting represents a differentiated approach compared to conventional checkpoint inhibitors and other cancer therapies in development.
Industry Context
Boundless Bio, Inc. operates in Pharmaceutical/Biotechnology - Clinical-Stage Oncology.
Key facts
Founded: 2018 · Headquarters: San Diego, US · Employees: 64 · Market cap: $24.4M